Skip to main content
. 2021 Nov 5;134(21):jcs258973. doi: 10.1242/jcs.258973

Fig. 5.

Fig. 5.

MyoII controls Cpa distribution. (A) Fixed embryos in interphase 13 injected with or without Rok inhibitor Y-27632, fixed and stained for F-actin (red) and CpaGFP (green). Red lines indicate the measurement by line profiles shown in B. (B) Normalized fluorescence intensity profiles of CpaGFP and F-actin in Y-27632-injected and control embryos. Six embryos were quantified per genotype (56 edges in control, 63 edges in Y-27632-injected embryos in total). Average is shown as a solid line, s.d. as a band. (C) Fitted exponential constant from intensity profiles of injected and control embryos. Corresponding averages and s.d. are shown by bars. **P≤0.001 (P-value was determined by two-tailed t-test). (D) Live wild-type and dia embryos expressing MyoII-GFP in interphase 13. Frontal sections of the cap and intercap layers are shown. (E) Wild-type and dia embryos in interphase 13 fixed and stained for F-actin (red) and MyoII-GFP (green). The images are maximum intensity projections. Scale bars: 10 µm.